Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New upgrade: Journal your trades with more detail

BioAtla, Inc.

Contributing Author

Recent Articles by BioAtla, Inc.

Mar-31	BioAtla Announces Share Consolidation BCAB BCAB -16.40% GlobeNewswire
Mar-31	BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights BCAB BCAB -16.40% GlobeNewswire
Mar-02	BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets BCAB -17.54% GlobeNewswire
Dec-31	BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) BCAB -20.82% GlobeNewswire
Nov-21	BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing BCAB -25.07% GlobeNewswire
Nov-13	BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress BCAB BCAB +19.75% GlobeNewswire
Nov-07	BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas BCAB +7.23% GlobeNewswire
Nov-05	BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 BCAB GlobeNewswire
Oct-23	BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society BCAB +9.39% GlobeNewswire
Oct-20	BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 BCAB -26.00% GlobeNewswire
Oct-03	BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 BCAB GlobeNewswire
Sep-08	BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA BCAB +13.92% GlobeNewswire
Aug-07	BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress BCAB BCAB -7.16% GlobeNewswire
Aug-04	BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 BCAB GlobeNewswire
Jul-17	BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting BCAB GlobeNewswire
Jul-03	BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress BCAB -5.43% GlobeNewswire
Jun-02	BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen BCAB +24.69% GlobeNewswire
May-06	BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress BCAB -8.19% BCAB -5.74% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)